By a News Reporter-Staff News Editor at Journal of Technology -- Researchers detail new data in Biomaterials. According to news reporting originating in Kaohsiung, Taiwan, by VerticalNews journalists, research stated, "Recent studies suggest that intratumoral legumain promotes tumorigenesis. To monitor legumain activity in tumors, we developed a new MM contrast agent ([Gd-NBCB-TTDA-Leg(L)]) and a NIR fluorescence probe (CyTE777-Leg(L)-CyTE807)."
The news reporters obtained a quote from the research from Kaohsiung Medical University, "The MRI contrast agent was prepared by introduction of cyclobutyl and benzyl group residues to TTDA (3,6,10-tri(carboxymethyl)-3,6,10-triaza-dodecanedioic acid), followed by the attachment of a legumain-specific substrate peptide (Leg(L)). The NIR fluorescence probe was designed by conjugating two NIR fluorochromes (CyTE777 and CyTE807) with Leg(L). Peptide cleavage of the MM contrast agent by legumain can increase its hydrophobicity and promote rotational correlation time (tauŽ). Peptide cleavage of the NIR probes by the legumain relieves the self quench of the probe. Peptide cleavage of the MRI contrast agent and the NIR fluorescence probe by legumain were confirmed by T-1 relaxometric studies and by fluorescence studies, respectively. In vivo MR images showed that [Gd-NBCB-TTDA-Leg(L)] attained 55.3 fold (254.2% versus 4.6%, at 2.0 h post-injection) higher imaging enhancement, as compared with control contrast agent bearing a noncleaveable peptide ([Gd-NBCB-TTDA-Leg(D)], in the CT-26 (legumain(+)) tumors. Similarly, optical imaging probe CyTE777-Leg(L)-CyTE807 attained 15.2 fold (3.34 x 10(9) photons/min versus 0.22 x 10(9) photons/min, at 24.0 h post-injection) higher imaging enhancement in the CT-26 (legumain(+)) tumors, compared to a NIR control probe (CyTE777-Leg(D)-CyTE807)."
According to the news reporters, the research concluded: "These data indicate that the [Gd-NBCB-TTDA-Leg(L)] and the CyTE777-Leg(L)-CyTE807 probes may be promising tools to image the legumain-expressing cancers for diagnoses and targeted treatments."
For more information on this research see: Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection. Biomaterials, 2014;35(1):304-315. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting Y.J. Chen, Kaohsiung Medical University, Kaohsiung Med Univ Hosp, Dept. of Obstet & Gynecol, Kaohsiung 807, Taiwan. Additional authors for this research include S.C. Wu, C.Y. Chen, S.C. Tzou, T.L. Cheng, Y.F. Huang, S.S. Yuan and Y.M. Wang.
Keywords for this news article include: Asia, Taiwan, Kaohsiung, Biomaterials
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC